Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity.

Jordan VC, Collins MM, Rowsby L, Prestwich G.

J Endocrinol. 1977 Nov;75(2):305-16.

PMID:
591813
2.
4.

Comparison of the biological effects of tamoxifen and a new antioestrogen (LY 117018) on the immature rat uterus.

Wakeling AE, O'Connor KM, Newboult E.

J Endocrinol. 1983 Dec;99(3):447-53.

PMID:
6644235
5.

Antioestrogenic and antitumour activities of a series of non-steroidal antioestrogens.

Wakeling AE, Valcaccia B.

J Endocrinol. 1983 Dec;99(3):455-64.

PMID:
6644236
7.

[The elucidation of the antiestrogen and antitumoral mechanisms of tamoxifen].

Borgna JL.

Bull Cancer. 1994 Jan;81(1):29-37. Review. French.

PMID:
7949581
8.

Interaction of spironolactone with oestradiol receptors in cytosol.

Levy J, Burshell A, Marbach M, Afllalo L, Glick SM.

J Endocrinol. 1980 Mar;84(3):371-9.

PMID:
7391714
9.
11.

Pharmacological characterization of a novel oestrogen antagonist, ZK 119010, in rats and mice.

Nishino Y, Schneider MR, Michna H, von Angerer E.

J Endocrinol. 1991 Sep;130(3):409-14.

PMID:
1834757
12.
13.
14.
15.

Identification and biological activity of tamoxifen metabolites in human serum.

Kemp JV, Adam HK, Wakeling AE, Slater R.

Biochem Pharmacol. 1983 Jul 1;32(13):2045-52.

PMID:
6870933
18.
19.
20.

Structural derivatives of tamoxifen and oestradiol 3-methyl ether as potential alkylating antioestrogens.

Jordan VC, Fenuik L, Allen KE, Cotton RC, Richardson D, Walpole AL, Bowler J.

Eur J Cancer. 1981 Feb;17(2):193-200. No abstract available.

PMID:
7262157

Supplemental Content

Support Center